Stay updated with breaking news from Singular Genomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOYA (OTCMKTS:HOCPY – Get Rating) and Singular Genomics Systems (NASDAQ:OMIC – Get Rating) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Volatility & Risk HOYA has a beta of […]
Revvity (NYSE:RVTY – Get Rating) and Singular Genomics Systems (NASDAQ:OMIC – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a breakdown of recent ratings and […]
Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Revvity (NYSE:RVTY – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Valuation and Earnings This table compares Singular Genomics Systems and […]
Singular Genomics Systems, Inc. (NASDAQ:OMIC – Get Rating) insider Eli N. Glezer purchased 170,000 shares of the stock in a transaction on Wednesday, May 17th. The stock was acquired at an average price of $0.82 per share, with a total value of $139,400.00. Following the completion of the acquisition, the insider now directly owns 4,355,000 […]
Rapid Micro Biosystems (NASDAQ:RPID – Get Rating) and Singular Genomics Systems (NASDAQ:OMIC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Analyst Recommendations This is a summary of […]